KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Jazz Pharmaceuticals (JAZZ) Accumulated Depreciation & Amortization (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Accumulated Depreciation & Amortization data on record, last reported at $41.6 million in Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 26.83% year-over-year to $41.6 million; the TTM value through Dec 2025 reached $41.6 million, up 26.83%, while the annual FY2025 figure was $41.6 million, 26.83% up from the prior year.
  • Accumulated Depreciation & Amortization reached $41.6 million in Q4 2025 per JAZZ's latest filing, up from $32.8 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $70.0 million in Q1 2021 and bottomed at $26.7 million in Q4 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $38.6 million, with a median of $31.6 million recorded in 2024.
  • Peak YoY movement for Accumulated Depreciation & Amortization: soared 42.78% in 2021, then grew 0.33% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $26.7 million in 2021, then increased by 13.48% to $30.3 million in 2022, then rose by 0.33% to $30.4 million in 2023, then rose by 7.89% to $32.8 million in 2024, then rose by 26.83% to $41.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $41.6 million in Q4 2025, $32.8 million in Q4 2024, and $30.4 million in Q4 2023.